Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct families of carbonic anhydrase enzymes (CAs) have so far been identified. Numerous physiological and pathological processes involve carbonic anhydrases. Many of them have the potential to be inhibited as effective therapeutic targets for the treatment of a variety of diseases, including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.
The carbonic anhydrase reaction is involved in a variety of physiological and pathological processes, including bone resorption, calcification, tumorigenicity, pH and CO2 homeostasis, electrolyte secretion in various tissues and organs, and respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs. Zn2+ metalloproteins known as -CAs are found in a wide range of organisms, including plants, prokaryotes, fungi, algae, and protozoa. Numerous diseases, including glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc., have been linked to sixteen mammalian -CA isoforms.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V80084 | hCAIX/XII-IN-7 | hCAIX/XII-IN-7 (compound 3e) is a potent inhibitor of hCA IX and XII with Ki of 3.2 nM, 9.2 nM, 503.7 nM and 59 nM for hCA I, hCA II, hCA IX and hCA XII respectively . | |
|
V73758 | hCAIX/XII-IN-8 | 59994-64-8 | hCAIX/XII-IN-8 (compound 3g) is a potent inhibitor of human (carbonic anhydrase) CA IX and XII with Kis of 8.5 and 6.7 nM, respectively. |
|
V85703 | hCAIX/XII-IN-9 | ||
|
V78733 | hCAXII-IN-7 | hCAXII-IN-7 (compound 6e) is an hCA XII inhibitor. | |
|
V81852 | Keap1-Nrf2-IN-3 | 2095066-47-8 | Keap1-Nrf2-IN-3 is an inhibitor (blocker/antagonist) of KEAP1:NRF2 protein-protein interaction and has Kd of 2.5 nM for KEAP1 protein. |
|
V81853 | m-PEG-NHS ester (MW 2000) | 92451-01-9 | m-PEG-NHS ester (MW 2000) may be utilized to modify active molecules and improve their antigenicity and immunogenicity to help prepare injectable preparations. |
|
V85662 | N-Desethyl Brinzolamide oxalate (AL-8520 oxalate) | 2775292-24-3 | |
|
V79696 | NSC 828467 | NSC 828467 has significant in vitro anti-cancer activity and is one of the top five CA-IX inhibitors with IC50 of 27.2nM. | |
|
V86187 | O-Desmethyl Brinzolamide hydrochloride | 2967475-56-3 | |
|
V85665 | Sulclamide | 2455-92-7 | |
|
V73750 | Sulthiame-d4 (Sulthiame-d4) | 1795021-05-4 | Sulthiame-d4 is the deuterium labelled form of Sulthiame. |
|
V73768 | β-Glucuronidase/hCAII-IN-1 | 2816080-17-6 | β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent inhibitor of β-glucuronidase and hCA II with IC50 of 440.1 μM and 4.91 μM, respectively. |
|
V73765 | β-Glucuronidase/hCAII-IN-2 | 2816080-13-2 | β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent inhibitor of β-glucuronidase and hCA II with IC50 of 670.7 μM and 21.77 μM, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
